Get the Stockscreener App
109.24
0.19%
0.21
After Hours:
109.24
Cidara Therapeutics Inc stock is traded at $109.24, with a volume of 547.50K.
It is up +0.19% in the last 24 hours and up +14.08% over the past month.
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.
See More
Previous Close:
$109.03
Open:
$108.88
24h Volume:
547.50K
Relative Volume:
0.68
Market Cap:
$2.77B
Revenue:
$302.00K
Net Income/Loss:
$-117.10M
P/E Ratio:
-9.8149
EPS:
-11.13
Net Cash Flow:
$-129.13M
1W Performance:
+17.31%
1M Performance:
+14.08%
6M Performance:
+423.05%
1Y Performance:
+740.31%
1-Day Range:
$106.70
$113.00
1-Week Range:
$94.50
$113.00
52-Week Range:
$12.66
$121.21
Cidara Therapeutics Inc Stock (CDTX) Company Profile
Name
Cidara Therapeutics Inc
Sector
Industry
Phone
858-752-6170
Address
6310 NANCY RIDGE DRIVE, SAN DIEGO, CA
Compare CDTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CDTX
Cidara Therapeutics Inc
|
109.24 | 2.76B | 302.00K | -117.10M | -129.13M | -11.13 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Cidara Therapeutics Inc Stock (CDTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-16-25 | Initiated | Morgan Stanley | Overweight |
| Oct-10-25 | Initiated | JP Morgan | Overweight |
| Jun-18-25 | Resumed | H.C. Wainwright | Buy |
| Mar-12-25 | Initiated | Citizens JMP | Mkt Outperform |
| Jan-27-25 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-13-24 | Initiated | RBC Capital Mkts | Outperform |
| Nov-08-24 | Initiated | Guggenheim | Buy |
| Aug-14-24 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Dec-03-21 | Resumed | H.C. Wainwright | Buy |
| Sep-22-21 | Upgrade | WBB Securities | Buy → Strong Buy |
| Mar-04-21 | Initiated | Aegis Capital | Buy |
| Sep-04-19 | Upgrade | Wedbush | Neutral → Outperform |
| Jul-26-18 | Initiated | Citigroup | Buy |
| Apr-21-17 | Initiated | Raymond James | Strong Buy |
| Apr-17-17 | Reiterated | H.C. Wainwright | Buy |
| Apr-12-17 | Initiated | Ladenburg Thalmann | Buy |
| Apr-11-17 | Resumed | Wedbush | Outperform |
| Feb-22-17 | Reiterated | H.C. Wainwright | Buy |
| Feb-22-17 | Upgrade | WBB Securities | Sell → Hold |
| Dec-21-16 | Resumed | Leerink Partners | Outperform |
| Dec-19-16 | Initiated | H.C. Wainwright | Buy |
| Sep-23-16 | Downgrade | WBB Securities | Hold → Sell |
| Oct-09-15 | Upgrade | WBB Securities | Sell → Hold |
| May-11-15 | Initiated | Jefferies | Buy |
| May-11-15 | Initiated | Leerink Partners | Outperform |
| May-11-15 | Initiated | Needham | Buy |
| May-11-15 | Initiated | Wedbush | Outperform |
| Apr-23-15 | Initiated | WBB Securities | Sell |
View All
Cidara Therapeutics Inc Stock (CDTX) Latest News
Does Cidara Therapeutics Inc. stock trade at a discount to peersJuly 2025 Market Mood & Real-Time Volume Trigger Notifications - newser.com
AlphaQuest LLC Makes New Investment in Cidara Therapeutics, Inc. $CDTX - MarketBeat
Jennison Associates LLC Invests $2.40 Million in Cidara Therapeutics, Inc. $CDTX - MarketBeat
Should you hold or exit Cidara Therapeutics Inc. nowMarket Rally & Fast Exit Strategy with Risk Control - newser.com
Signal strength of Cidara Therapeutics Inc. stock in tech scannersJuly 2025 Selloffs & Consistent Income Trade Ideas - newser.com
How Cidara Therapeutics Inc. stock benefits from strong dollarNew Guidance & Free Technical Pattern Based Buy Signals - newser.com
What to do if you’re stuck in Cidara Therapeutics Inc.July 2025 Momentum & AI Powered Market Trend Analysis - newser.com
Cidara Therapeutics (CDTX): Assessing Valuation After FDA Breakthrough Therapy Nod and New BARDA Support - Sahm
Cidara Therapeutics (CDTX) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
What hedge fund moves indicate for Cidara Therapeutics Inc. (20D0) stockEarnings Summary Report & Daily Stock Momentum Reports - newser.com
Published on: 2025-10-31 05:10:02 - newser.com
How Cidara Therapeutics Inc. stock compares to growth peersWeekly Stock Summary & Free Weekly Chart Analysis and Trade Guides - newser.com
Will Cidara Therapeutics Inc. stock outperform international peers2025 Big Picture & Safe Entry Momentum Tips - newser.com
Why Cidara Therapeutics Inc. stock is in analyst buy zone2025 Bull vs Bear & Consistent Income Trade Recommendations - newser.com
Will Cidara Therapeutics Inc. stock deliver long term returns2025 Pullback Review & Reliable Price Breakout Alerts - newser.com
How to escape a deep drawdown in Cidara Therapeutics Inc.2025 Historical Comparison & Stock Portfolio Risk Management - newser.com
Is Cidara Therapeutics Inc. forming a bottoming base2025 Risk Factors & Safe Capital Growth Trade Ideas - newser.com
Using Ichimoku Cloud for Cidara Therapeutics Inc. technicalsJuly 2025 Short Interest & AI Powered Buy/Sell Recommendations - newser.com
Cidara Therapeutics (CDTX) Price Target Increased by 24.94% to 167.79 - Nasdaq
How risky is Cidara Therapeutics Inc. stock now2025 Volatility Report & Low Drawdown Momentum Trade Ideas - newser.com
Cidara Therapeutics (NASDAQ:CDTX) Trading 8.2% HigherHere's What Happened - MarketBeat
Cidara Therapeutics to Participate in November Investor Conferences - The Manila Times
Cidara Therapeutics Inc Stock (CDTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.62%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):